MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 465551 | Name: LNP599 HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LNP599 HCl is a novel potent and specific agonist of I1 imidazoline receptors.

Chemical Structure

LNP599 HCl
LNP599 HCl
CAS#unknown

Theoretical Analysis

MedKoo Cat#: 465551

Name: LNP599 HCl

CAS#: unknown

Chemical Formula: C12H16Cl2N2

Exact Mass: 258.0691

Molecular Weight: 259.17

Elemental Analysis: C, 55.61; H, 6.22; Cl, 27.36; N, 10.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
LNP599 HCl; LNP 599 HCl; LNP-599 HCl; LNP599 hydrochloride; LNP-599 hydrochloride; LNP 599 hydrochloride;
IUPAC/Chemical Name
N-(3-chloro-2-methylphenyl)-3-methyl-3,4-dihydro-2H-pyrrol-5-amine hydrochloride
InChi Key
HGKOVGUOLPCPLM-UHFFFAOYSA-N
InChi Code
InChI=1S/C12H15ClN2.ClH/c1-8-6-12(14-7-8)15-11-5-3-4-10(13)9(11)2;/h3-5,8H,6-7H2,1-2H3,(H,14,15);1H
SMILES Code
ClC1=C(C)C(NC2=NCC(C)C2)=CC=C1.Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 259.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Bousquet P, Hudson A, García-Sevilla JA, Li JX. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacol Rev. 2020 Jan;72(1):50-79. doi: 10.1124/pr.118.016311. PMID: 31819014. 2: Weiss M, Fellmann L, Regnard P, Bousquet P, Monassier L, Niederhoffer N. Protective effects of the imidazoline-like drug lnp599 in a marmoset model of obesity-induced metabolic disorders. Int J Obes (Lond). 2021 Jun;45(6):1229-1239. doi: 10.1038/s41366-021-00786-6. Epub 2021 Mar 2. PMID: 33654274. 3: Nascimento AR, Gomes F, Machado MV, Gonçalves-de-Albuquerque C, Bousquet P, Tibiriçá E. I1-imidazoline receptor-mediated cardiovascular and metabolic effects in high-fat diet-induced metabolic syndrome in rats. Auton Neurosci. 2019 Mar;217:18-25. doi: 10.1016/j.autneu.2018.12.007. Epub 2018 Dec 22. PMID: 30704971. 4: Fellmann L, Regnault V, Greney H, Gasparik V, Muscat A, Max JP, Gigou L, Oréa V, Chetrite G, Pizard A, Niederhoffer N, Julien C, Lacolley P, Fève B, Bousquet P. A new pyrroline compound selective for I1-imidazoline receptors improves metabolic syndrome in rats. J Pharmacol Exp Ther. 2013 Sep;346(3):370-80. doi: 10.1124/jpet.113.205328. Epub 2013 Jul 1. Erratum in: J Pharmacol Exp Ther. 2013 Oct;347(1):249. PMID: 23818682. 5: Aubertin G, Weiss M, Traversi F, Benameur D, Choquet P, Dali-Youcef N, Pons F, Sigrist S, Greney H, Monassier L, Bousquet P, Niederhoffer N. Effects of imidazoline-like drugs on liver and adipose tissues, and their role in preventing obesity and associated cardio-metabolic disorders. Int J Obes (Lond). 2019 Nov;43(11):2163-2175. doi: 10.1038/s41366-019-0342-z. Epub 2019 Mar 29. PMID: 30926950. 6: Estato V, Nascimento A, Antunes B, Gomes F, Coelho L, Rangel R, Garzoni L, Daliry A, Bousquet P, Tibiriçá E. Cerebral Microvascular Dysfunction and Inflammation Are Improved by Centrally Acting Antihypertensive Drugs in Metabolic Syndrome. Metab Syndr Relat Disord. 2017 Feb;15(1):26-35. doi: 10.1089/met.2016.0085. Epub 2016 Dec 8. PMID: 27929741. 7: Gasparik V, Greney H, Schann S, Feldman J, Fellmann L, Ehrhardt JD, Bousquet P. Synthesis and biological evaluation of 2-aryliminopyrrolidines as selective ligands for I1 imidazoline receptors: discovery of new sympatho-inhibitory hypotensive agents with potential beneficial effects in metabolic syndrome. J Med Chem. 2015 Jan 22;58(2):878-87. doi: 10.1021/jm501456p. Epub 2014 Dec 31. PMID: 25521963.